ELDN

Eledon Pharmaceuticals, Inc. develops therapies aimed at improving outcomes for patients undergoing kidney transplantation. The company is advancing tegoprubart, a therapeutic in clinical development designed to extend the functional life of transplanted organs and reduce side effects associated with current immunosuppressive treatments. Eledon focuses on addressing the challenges faced by kidney transplant recipients, including the cycle of end-stage renal disease and the need for effective immunosuppressant therapies.